Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Intangibles: 2010-2025

Historic Intangibles for Anika Therapeutics (ANIK) over the last 15 years, with Sep 2025 value amounting to $15.7 million.

  • Anika Therapeutics' Intangibles fell 68.49% to $15.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.7 million, marking a year-over-year decrease of 68.49%. This contributed to the annual value of $2.5 million for FY2024, which is 87.45% down from last year.
  • Per Anika Therapeutics' latest filing, its Intangibles stood at $15.7 million for Q3 2025, which was down 0.00% from $15.7 million recorded in Q2 2025.
  • Anika Therapeutics' Intangibles' 5-year high stood at $112.7 million during Q1 2021, with a 5-year trough of $15.7 million in Q2 2025.
  • For the 3-year period, Anika Therapeutics' Intangibles averaged around $55.8 million, with its median value being $49.9 million (2024).
  • Data for Anika Therapeutics' Intangibles shows a maximum YoY slumped of 82.31% (in 2023) over the last 5 years.
  • Anika Therapeutics' Intangibles (Quarterly) stood at $112.7 million in 2021, then dropped by 0.53% to $112.1 million in 2022, then plummeted by 82.31% to $19.8 million in 2023, then tumbled by 55.46% to $49.9 million in 2024, then plummeted by 68.49% to $15.7 million in 2025.
  • Its Intangibles stands at $15.7 million for Q3 2025, versus $15.7 million for Q2 2025 and $20.4 million for Q1 2025.